Orion Pharma (DHA:ORIONPHARM) E10: BDT2.96 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:ORIONPHARM Orion Pharma Ltd DHA:ORIONPHARM
72 GF Score
Price BDT30.10
GF Value BDT20.18
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Orion Pharma E10?

Orion Pharma DHA:ORIONPHARM -2.27% 72 E10 is BDT2.96 as of Mar. 2026. GuruFocus rates DHA:ORIONPHARM with a GF Score™ of 72/100 and a GF Value™ of BDT20.18 (Significantly Overvalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Orion Pharma's adjusted earnings per share data for the three months ended in Mar. 2026 was BDT-0.650. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is BDT2.96 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Orion Pharma's average E10 Growth Rate was -18.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-07-13), Orion Pharma's current stock price is BDT30.10. Orion Pharma's E10 for the quarter that ended in Mar. 2026 was BDT2.96. Orion Pharma's Shiller PE Ratio of today is 10.17.

During the past 12 years, the highest Shiller PE Ratio of Orion Pharma was 20.07. The lowest was 7.02. And the median was 9.84.


Orion Pharma  (DHA:ORIONPHARM) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Orion Pharma's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=30.10/2.96
=10.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Shiller P/E Ratio of Orion Pharma was 20.07. The lowest was 7.02. And the median was 9.84.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Orion Pharma E10 Related Terms


Orion Pharma E10 Historical Data

* Premium members only.

The historical data trend for Orion Pharma's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orion Pharma E10 Chart

Orion Pharma Annual Data
Trend Dec14 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 4.35 4.06 3.39

Orion Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.62 3.39 3.32 3.06 2.96

DHA:ORIONPHARM vs CEG, VST, NRG: E10 Comparison

For the Utilities - Independent Power Producers subindustry, Orion Pharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orion Pharma Shiller PE Ratio vs Utilities - Independent Power Producers Industry

For the Utilities - Independent Power Producers industry and Utilities sector, Orion Pharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Orion Pharma's Shiller PE Ratio falls into.


DHA:ORIONPHARM
72GF Score
Orion Pharma Ltd DHA:ORIONPHARM
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orion Pharma E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Orion Pharma's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.65/330.2130*330.2130
=-0.650

Current CPI (Mar. 2026) = 330.2130.

Orion Pharma Quarterly Data

per share eps CPI Adj_EPS
201509 0.730 237.945 1.013
201609 1.170 241.428 1.600
201612 1.290 241.432 1.764
201703 0.560 243.801 0.758
201706 0.376 244.955 0.507
201709 1.100 246.819 1.472
201712 0.970 246.524 1.299
201803 0.690 249.554 0.913
201806 0.666 251.989 0.873
201809 0.980 252.439 1.282
201812 1.080 251.233 1.420
201903 0.950 254.202 1.234
201906 0.760 256.143 0.980
201909 1.170 256.759 1.505
201912 0.970 256.974 1.246
202003 0.950 258.115 1.215
202006 0.090 257.797 0.115
202009 0.820 260.280 1.040
202012 1.210 260.474 1.534
202103 0.950 264.877 1.184
202106 1.030 271.696 1.252
202109 0.300 274.310 0.361
202112 1.720 278.802 2.037
202203 1.050 287.504 1.206
202206 0.547 296.311 0.610
202209 0.720 296.808 0.801
202212 1.190 296.797 1.324
202303 0.530 301.836 0.580
202306 0.296 305.109 0.320
202309 0.760 307.789 0.815
202312 0.470 306.746 0.506
202403 0.420 312.332 0.444
202406 -0.291 314.175 -0.306
202409 0.240 315.301 0.251
202412 -0.440 315.605 -0.460
202503 0.020 319.799 0.021
202506 -1.598 322.561 -1.636
202509 -0.300 324.800 -0.305
202512 -0.560 324.054 -0.571
202603 -0.650 330.213 -0.650

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of BDT2.96 mean?
Orion Pharma (DHA:ORIONPHARM) has a E10 of BDT2.96 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Orion Pharma and its competitors.
Is Orion Pharma's E10 too high?
Orion Pharma's current E10 is BDT2.96. Overall, Orion Pharma has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's E10 compare to CEG and VST?
Orion Pharma's E10 of BDT2.96 can be compared against companies in the Utilities - Independent Power Producers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for an Utilities - Independent Power Producers company?
A good E10 depends on the Utilities - Independent Power Producers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Orion Pharma and its competitors. Orion Pharma's current E10 is BDT2.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Significantly Overvalued. The stock's GF Value™ is BDT20.18, compared to a current price of BDT30.10 — trading 49.2% above its estimated fair value. The current E10 is BDT2.96. Orion Pharma's overall GF Score™ is 72/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current E10 is BDT2.96 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued. The current stock price of BDT30.10 is trading 49.2% above its estimated GF Value™ of BDT20.18. GuruFocus considers Orion Pharma to be Significantly Overvalued.

Key valuation signals for DHA:ORIONPHARM:

  • E10: BDT2.96
  • GF Value™: BDT20.18 vs. price of BDT30.10 (49.2% above fair value)
  • GF Score™: 72/100 with 8 warning signs

No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Orion Pharma Business Description

Address 153-154 Tejgaon Industrial Area, Orion House, Dhaka, BGD, 1208
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
72GF Score

Get the complete analysis for DHA:ORIONPHARM

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT30.10
Price
BDT20.18
GF Value